Trial Profile
A randomized, double dummy controlled, parallel group study of the efficacy and safety of MabThera (rituximab) alone or in combination with either cyclophosphamide or methotrexate, in patients with rheumatoid arthritis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Mar 2014
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Cyclophosphamide; Methotrexate
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Genentech; Roche
- 27 Mar 2014 New trial record